Drug Approval | February 14, 2022
Lilly's bebtelovimab receives EUA to treat mild-to-moderate Covid-19
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Adds five years of market exclusivity on approval
On track to complete the BLA submission in the first half of 2022
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
It has a total of 50 ANDA approvals from USFDA
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Subscribe To Our Newsletter & Stay Updated
